Hematlde" is a synthetic PEGylated peptidic erythropoiesis stimulating agent (ESA) that is presently being developed for the correction of anemia in patients with chronic renal failure. Unlike currently marketed ESAs, Hematide does not possess any sequence homology to erythropoietin (EPO) and has not elicited moribund immune responses in animal safety studies thereby allowing the generation of a robust safety package. Animals administered marketed ESAs develop anti-EPO antibodies that null the effect of the administered ESA and neutralize endogenous EPO, resulting in severe anemia that precludes the interpretation of chronic safety studies. The primary objective of this study is to determine whether Hematide-specific antibodies are generated when male monkeys are exposed to high Hematide doses (10 mg/kg, intravenous [IV] and subcutaneous [SCD administered at frequent dosing intervals (every two weeks) for a total of 9 doses; secondary objectives are to evaluate whether developed antibodies impact pharmacokinetics (PK) and pharmacology. In this study, no Hematide-specific antibodies were detected. Hematide exhibits a prolonged plasma half-life and slow clearance by either IV or SC administration. Hematide induced significant erythropoiesis with reticulocytosis and subsequent increases in red blood cells, hematocrit and hemoglobin (Hgb) levels. No erythropoietic differences were noted between the IV and the SC dosed groups with mean ± SD Hgb levels of 20.9 ± 2.5 and 20.3 ± 2.1 g/dL, respectively, occurring on Day 48, corresponding to Hgb increases of 6.5 and 6.7 g/dL, respectively, over pre-dose levels. In conclusion, Hematide is a potent erythropoiesis stimulating agent that exhibits plasma persistence in monkeys. Similar erythropoietic responses were produced following IV and SC administration. The absence of antibody development suggests that Hematide, at the doses and regimen described, has a low immunogenic potential in cynomolgus monkeys.
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Hematide was developed in part to overcome the shortcomings of approved erythropoietic agents, namely, short pharmacodynamic action and potential to cause antibodies against endogenous erythropoietin (4) . Hematide is an erythropoiesis stimulating agent (ESA) comprising a peptide portion, a novel linker-spacer, and polyethylene glycol (5) . In the clinical setting, recombinant EPO ESAs have been successful in managing stable hemoglobin (Hgb) levels, thereby avoiding the need for transfusions; however, in rare cases they have been associated with the development of anti-EPO antibody-mediated pure red cell aplasia (PRCA) (5) (6) .
Patients with drug-induced PRCA develop a profound transfusion-dependent anemia that is non-responsive to endogenous EPO, recombinant human EPO (rHuEPO) or EPO products with a related amino acid sequence. Hematide is an agonist of the EPO receptor, without having the immunological epitopes of EPO, and therefore is much less likely to induce a cross-reactive immune response against endogenous EPO. Hematide, like EPO, activates intracellular signaling cascades by inducing a receptor-complex conformational change that leads to the phosphorylation of the receptor and its associated kinase, Janus tyrosine kinase 2 (JAK2) (4) . Several intracellular signaling mediators are then activated, including signal transducers and activators of transcription 5A and 5B (STAT5A and STAT5B), PI3-kinase/AKT/Protein Kinase B, and mitogen activated protein kinase (MAPK).
The antibodies to Hematide or to Hematide protein conjugates, which have been raised in different animal species, do not cross react with rHuEPO. In addition, antibodies to EPO generated in humans and animals that result in PRCA do not cross react with Hematide (7) . By virtue of this lack of immunological cross-reactivity, Hematide was used to correct anemia in rats with anti-EPO antibodymediated PRCA (7) . Subsequently, in a clinical trial in patients with anti-EPO antibody-induced PRCA, monthly Hematide treatment maintains Hgb levels without the need for transfusions (5) .
To date, non-clinical data indicate minimal immunogenicity of Hematide. Because therapy for CRF can be life-long, or until successful kidney transplantation, vigilance needs to be maintained regarding the evaluation of possible adverse events associated with the production of Hematide-specific antibodies. To this end, this study was designed using a dosing program that would facilitate detection of immunogenicity of Hematide and then characterize potential modulatory or deleterious effect on safety, efficacy and pharmacokinetics.
MATERIALS AND METHODS

Study Design
All animals received care in compliance with Guide for the Care and Use of Laboratory Animals (NIH Publication, 1996) and the study was conducted under the auspices of an Internal Animal Care and Use Committee (IACUC). Ten male cynomolgus monkeys (Macacafascicularis) of Chinese origin from the SNBL USA (Everett, WA USA) stock colony, which were nonnaive to treatment with investigational drugs but naive to treatment with ESAs, and weighing between 4.34 -6.75 kg, were assigned to the study. Hematide was formulated in 10 mM acetate in isotonic saline, pH 5.5 (4) . The monkeys were assigned to one of two treatment groups (n=5 per group). Animals received either an IV bolus dose (10 mg/kg, 1 mL/kg) or subcutaneous (SC) dose of 10 mg Hematide/kg at a dose-volume of 1 mL/kg. Hematide (l0 mg/kg) was administered every two weeks (Q2W) for three 4-week cycles beginning on Days 1 (IV or SC), 71 (IV or SC), and 141 (SC); animals received a total of nine doses. There was a 42-day rest period between each cycle . . to allow for sample analyses and to allow Hematide serum concentrations to decline below levels that might interfere with the detection of antibody. Starting on Day 141, all animals were dosed via the SC route because ongoing evaluation of the data showed no antibody production, and the SC route is postulated to induce a greater immune response (compared to IV), (8) . One monkey (SSAN 10) received an additional dose of Hematide (l mg/kg IV) on Day 211 because it had shown a diminished response to Hematide dosing during the study. The study was concluded on Day 224. Blood samples were collected for pharmacokinetic, hematology, and Hematide-specific antibody evaluation. To reduce any potential adverse events associated with chronic polycythemia, 30 to 40 mL ofblood was collected on Days 48,78,92, 106, 120, 147, 161, 175, and 189 from sedated animals. Fluid volume was replaced with approximately 50 mL of SC saline.
Pharmacokinetics
Blood samples (1.0 mL) for pharmacokinetic analysis were collected pre-dose, and at 1, 4, 8, 24, 48, 72, 120, 168 , and 240 hours following the first dose on Day 1.The plasma samples were analyzed for Hematide using a competition ELISA assay with a lower limit of quantification of 40 ng/mL (4, 7) . Pharmacokinetic analysis was carried out using the Winblonlin'" software (version 4.1, Pharsight, Mountain View, CA, US) program.
Hematology and Serum Chemistry Analyses
Blood for hematology analysis was collected pre-dose and on Days 1, 6, 14, 28, 34, 48, 70, 84, 98, 112, 126, 140, 154, 168, 182 and 210 for all animals and on Days 215 and 224 from SSAN 10 only. Hematology samples were analyzed using an Advia 120 hematology system. Blood (1.0 mL) for serum chemistry analysis was collected from all animals on Day 210 and analyzed by an Olympus AU400 chemistry-immuno analyzer.
Antibody Analyses
Blood (1.0 mL) for antibody analysis was collected pre-dose and on Days 14,28,48, 70, 78, 84, 92, 98, 106, 112, 120, 126, 140, 147, 154, 161, 168, 175, 182, 189, and 210, and on Days 213 and 219 from SSAN 10 only. Detection of Hematide-specific antibodies was performed using an antibody detection ELISA that is capable of detecting positive control antibodies with a sensitivity of approximately 200 ng/mL (4, 7, 9) . Serum samples diluted 1:10 were incubated in Hematide-coated microplate wells, washed, probed with goat-anti-monkey IgG alkaline phosphatase conjugate, and developed with a colorimetric substrate. The overall non-specific binding (NSB) for each assay day was determined by calculating the mean and standard deviation of the signals from the pre-dose samples. The signal cut point was defined for that assay day as the NSB plus 3 standard deviations. Post-dose samples were considered to be preliminary positives, subject to a further test to determine their binding specificity, if the signal was greater than the signal cut point and also significantly greater than the signal from the corresponding pre-dose sample. From a total of 250 samples tested, 17 (6.8%) scored preliminary positive in the ELISA testing to detect IgG or IgM.
Preliminary positives were then taken through a second specificity confirmation step to distinguish Hematidespecific binding from non-specific binding. Serum samples were pre-incubated for 30 minutes in the presence of 50 ug/ml, Hematide (competed) or in the presence of an equivalent amount of formulation buffer (uncompeted) in undiluted and I: 10 diluted form, followed by a further 1:10 dilution in assay buffer for testing at final 1:10 and 1:100 dilutions. From each sample dilution, a Specificity Ratio was calculated, defined as the mean signal from uncompeted wells divided by the mean signal from competed wells. Binding was considered to be specific for Hematide, and the sample confirmed positive, if the Specificity Ratio was greater than 2.0 from either the 1:10 or the 1:100 diluted sample. Due to the observation that all of the animals scored negative for Hematide-specific IgG antibodies, all samples with sufficient available volume were tested again with development using a secondary antibody specific for monkey IgM.
Assay qualification and validation studies have revealed that this ELISA is capable ofdetecting antibodies specific for the peptide or PEG components of Hematide (data not shown). The ELISA is, however, subject to interference by Hematide present in serum samples: 30 ng/mL of Hematide in 100% monkey serum inhibits by 50% the signal from 150 ng/mL of the positive control antibody. The specificity confirmation step has been shown to yield positive results with the positive control antibody at concentrations ranging from 200 ng/mL up to 100 ug/ml, (data not shown). Binding of PEG-specific positive control antibodies to the micro-plate wells is also inhibited under the conditions used for specificity confirmation.
RESULTS
Clinical Observations
No untoward Hematide-related clinical observations were observed during the course of the study indicating Hematide treatment was well tolerated.
Immunogenicity
Hematide was dosed at 10 mg/kg every two weeks for a total of 9 doses, with rest periods after the third and sixth doses to allow serum concentrations of Hematide to decline below levels (30 ng/mL) that might interfere with the antibody detection direct ELISA. Five animals were given six IV doses followed by three SC doses while the other five animals were given all nine doses by the SC route. Samples from 20 time points were tested, and no Hematide-specific IgG antibodies were detected. Subsequent testing of all available samples for Hematide-specific IgM antibodies also yielded negative results.
Pharmacokinetics
The pharrnacokinetic parameters of Hematide following single IV and SC administration are summarized in Table I and are depicted in Fig. 1 . Following IV bolus administration, disappearance of Hematide from plasma occurred in a bi-exponential fashion, with a rapid initial phase followed by a dominant, prolonged terminal phase. The mean apparent terminal half-life following a 10 mg/kg IV dose was 114 h with Hematide plasma concentration at the last sampling time (240 h) of 86 ug/ml.. The plasma clearance estimate was small, with a mean value of 0.17 mlzh-kg. The volume of distribution at steady state (V ss ) was' also small, 25.9 mLlkg. This small V ss (approximating plasma volume) indicates that Hematide is confined to the plasma compartment (10) . Hematide was absorbed slowly following SC injection in monkeys, with a delayed pseudo C max at 48 to 168 h. Absorption following SC administration was extremely slow and resulted in a plateau plasma concentration profile throughout the entire PK sampling interval of 240 h (10 days). A terminal elimination half life was not reached even at 169 h post dose. Therefore, longer sampling times are required to fully characterize the SC pharmacokinetic parameters at the studied dose of 10 mg/kg. The SC bioavailability, estimated by AUC 240h after IV and SC administration, was 57.1%.
Pharmacology
Hematide induced significant erythropoiesis with characteristic increases in reticulocytes, followed by subsequent increases in red blood cells (RBCs), hematocrit (Hct) and Hgb levels. Hematologic parameters through the first 70 days are displayed in Fig.2 . No erythropoietic differences were noted between the IV and SC administration dose groups. Hematide administration caused a significant increase in the number of circulating reticulocytes correlating with the expected stimulation, timing and release of reticulocytes from the bone marrow into the systemic circulation. The largest increase in reticulocytes occurred on Day 14, with mean ± SD percent reticulocytes of9.1 ± 2.1 and 9.6 ± 0.8 following IV and SC administration, respectively, compared to 1.0 ± 0.2 and 1.4 ± 0.5 levels at predose. Levels declined to basal, pre-dose levels on Day 70, correlating to 41 days following the third administration on Day 29. Subsequent reticulocyte maturation into RBCs was evidenced by large increases in RBCs with associated increases in Hgb and Hct levels. Beginning on Day 14, Hgb levels were significantly greater than pre-dose levels; mean ± SD levels for the IV and SC groups were 16.9 ± 0.6 and 17.8 ± 1.5 g/dL, respectively, corresponding to mean Hgb increases of 2.5 and 3.2 g/dL. Hgb levels progressively increased to a plateau of approximately 20-22 g/dL by Day 34. These levels were sustained through Day 70, at which time the mean ± SD Hgb levels were 21.5 ± 1.6 and 20.9 ± 2.4 g/dL for the SC and IV groups, respectively, corresponding to increases of 6.9 and 6.5 g/dL over pre-dose levels. The temporal profiles for percent reticulocytes and Hgb levels are shown in Fig. 3 . Reticulocyte changes display a synchronicity with dosing; at approximately 5 through 30 days following each dose administration, reticulocytes levels remained elevated and declined to baseline levels at approximately 41 days following dosing. The latter is in line with maturation of the reticulocytes into RBCs in the systemic circulation. Hgb levels remained at plateau levels throughout the dosing period despite extensive phlebotomy procedures. Hemoglobin levels were maintained up to Day 210. Additional cycles of Hematide did not produce further increases in Hgb.
Red blood cell morphologies and secondary hematologic indices were consistent with erythropoiesis and polycythemia. Changes in secondary hematologic indices, included an approximate 10% increase in mean corpuscular volume (MCV) and a slight decrease in mean corpuscular Hgb content (MCHC), and are consistent with anticipated RBC rheologic changes following accelerated erythropoiesis.
Pharmacologic Variance
While the IV and SC groups exhibited similar hematological parameters, closer inspection showed that the IV group had a larger standard deviation, and individual analyses revealed that one monkey (SSAN 10) had responded less robustly. Fig. 4 depicts the hematologic profile of SSAN 10 compared to its cohorts. The Hgb levels in SSAN 10 began to decline after Day 34, reaching baseline by approximately Day 98, with further decline below baseline after Day 155 and a slow recovering after the last phlebotomy (30 to 40 mL blood collection). As SSAN 10 was not polycythemic, continued phlebotomies may have exaggerated the appearance of hyporesponsiveness. On Day 211, SSAN 10 was administered an IV dose of 1 mg/kg and responded with an increase in reticulocytes, (0.4% on Day 210 to 2.7% on Day 224) and subsequent increase in Hgb Because SSAN 10 responded to Hematide on Day 211, and together with an absence of Hematidespecific antibodies, this response suggested the phenomenon was not related to immunogenicity. SSAN 10, however, did exhibit decreases in MCH levels, with a continuous increase in platelet counts from Day 1 (509 x 103/ Il L), to a peak on Day 168 (1848 x 103/ Il L) ( Fig. 4 ). This was followed by a decline to baseline levels on Day 210 (41 days following the previous dose) with a rebound following dosing on Day 210 to platelet levels of 1614 x 103/ Il L on Day 224.
DISCUSSION
The patient population for CKD is comprised of individuals with end-stage renal disease who are on dialysis, as well as earlier stage CKD patients and patients not on dialysis. The anemia in affected patients is chronic in nature and requires long term therapeutic support. Hematide is a synthetic peptide-based, PEGylated ESA that is specifically designed to bind and activate the EPO receptor, resulting in production of RBCs (4) . Nonclinically, Hematide exhibits a prolonged half-life, sustained pharmacological activity, and minimal immunogenicity. Clinically, Hematide is presently undergoing evaluation for the correction of anemia in CKD patients on dialysis and not on dialysis (11) .
Many marketed or investigational therapeutic proteins induce immunogenicity (12) (13) . Antidrug antibody formation may present a potential risk of compromising drug safety, efficacy and pharmacokinetics, therefore efforts need to be made during development to understand, and offset, any potential risks. In the case of ESAs, recombinant human EPO has caused PRCA by inducing crossreactive antibodies that neutralize the biological activity of endogenous erythropoietin (5) (6) . Also, with currently marketed EPOs, non-clinical chronic study findings are confounded by immunogenic interference.
For example, the administration of rHuEPO to cynomolgus monkeys causes a potent immune response, despite a 92% amino acid homology between human and monkey EPO, resulting in the generation ofanti-rHuEPO antibodies, and thereby suppressing Hgb responses (14) . Such immunogenic-induced morbidity precludes the rigorous safety assessment of conventional ESAs in regulatory-required chronic non-clinical studies.
Antibodies to Hematide have not been observed in rats regardless of dose, route, dose frequency or duration of dosing (15) . However, Hematidespecific antibodies have been observed in monkey studies at relatively high Hematide doses, or with frequent dosing (16) (17) . Two animals were found positive for Hematide-specific antibodies following IV weekly dosing at 0.5 and 50 mg/kg/dose for 5 weeks, (16) and three were deemed positive (one positive and two likely) following every 3-week up to 9-month IV dosing at 20 mg/kg (17) . The presence of antibodies in these animals did not suppress the in vivo pharmacologic response to Hematide compared to antibody-negative monkeys, nor was there any toxicity or change in pharmacokinetics associated with the presence ofthe Hematide-specific antibodies in these animals. Also importantly, these Hematidespecific antibodies did not cross-react with rHuEPO, and therefore they would hot be expected to interfere with erythropoiesis driven either by endogenous EPO or marketed ESAs (e.g., recombinant Epoetin).
Hematide exhibits sustained plasma 'persistence following both IV and SC 10 mg/kg administration. The half-life following IV administration was long, at 114 h compared to rHuEPO at 2.5 hr (18) . Hematide induced accelerated reticulocytosis resulting in Hgb levels that plateaued between 20-22 g/dL corresponding to approximately 7 g Hgb/dL above pre-dose levels. Pharmacologic profiles were similar following IV and SC administration. One animal, however, behaved differently from its group mates, displaying, a reduced response to Hematide over time. However, this finding may have been exaggerated as this animal was not polycythemic and continued blood sampling (phlebotomy) may have amplified the difference. Platelet increases and concurrent decreases in MCH are consistent with rheological changes following chronic accelerated reticulocytosis especially in individual with functional iron deficiency (19) .
Despite persistent attempts to induce Hematidespecific antibodies in this study, none were detected using the dose and dosing regimens employed and it may be that longer exposure is required. These data confirm results to date, indicating minimal immunogenicity of Hematide during nonclinical studies, thus enabling characterization of meaningful chronic non-clinical safety data that are not confounded by immunogenic interference. The lack of detectable immunological cross-reactivity between Hematide and rHuEPO suggests that even if Hematide-specific antibodies were produced, they would pose a minimal risk of inducing antibodies reactive with endogenous human erythropoietin (4).
